Table 4.
Multivariable analysis to assess the independent impact of thyroid hormone on AKI in patients with ASTAAD using none adjusted and adjusted logistic regression model.
| Crude Model | Model Ⅰ | Model ⅠⅠ | ||||
|---|---|---|---|---|---|---|
| OR(95%CI) | P-value | OR(95%CI) | P-value | OR(95%CI) | P-value | |
| TT3 (nmol/L) | 0.27 (0.04, 1.69) | 0.16 | 0.32 (0.05, 2.23) | 0.25 | 0.07 (0.01, 0.86) | 0.04* |
| TT4 (nmol/L) | 0.98 (0.96, 1.01) | 0.14 | 0.98 (0.96, 1.01) | 0.17 | 0.97 (0.94, 1.00) | 0.07 |
| TSH (mIU/L) | 1.06 (0.71, 1.59) | 0.76 | 1.03 (0.66, 1.61) | 0.89 | 1.00 (0.61, 1.64) | 0.98 |
| FT3 (pmol/L) | 0.71 (0.39, 1.30) | 0.27 | 0.88 (0.45, 1.70) | 0.69 | 0.71 (0.30, 1.66) | 0.43 |
| FT4 (pmol/L) | 0.98 (0.83, 1.16) | 0.82 | 0.97 (0.81, 1.15) | 0.69 | 0.96 (0.78, 1.19) | 0.72 |
Crude Model adjusted for: None.
Model I adjusted for: sex; age (years); body mass index (kg/m2)
Model II adjusted for: sex; age (years); body mass index (kg/m2); platelet (G/L); Hematocrit (%); creatinine (μmol/L); intraoperative transfusion of packed red blood cell (u); aortic cross-clamping time (min); circulatory arrest time (min).
*P value indicates significance at P < 0.05.